Braun Bostich & Associates Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 72.8% in the 2nd quarter, Holdings Channel reports. The firm owned 6,772 shares of the biopharmaceutical company’s stock after acquiring an additional 2,853 shares during the quarter. Braun Bostich & Associates Inc.’s holdings in Pfizer were worth $246,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Omnia Family Wealth LLC grew its holdings in shares of Pfizer by 15.5% during the second quarter. Omnia Family Wealth LLC now owns 31,961 shares of the biopharmaceutical company’s stock valued at $1,160,000 after purchasing an additional 4,296 shares during the last quarter. Great West Life Assurance Co. Can grew its holdings in shares of Pfizer by 4.9% during the second quarter. Great West Life Assurance Co. Can now owns 8,719,345 shares of the biopharmaceutical company’s stock valued at $316,683,000 after purchasing an additional 403,854 shares during the last quarter. Patton Albertson Miller Group LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $202,000. Dimensional Fund Advisors LP grew its holdings in shares of Pfizer by 15.0% during the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock valued at $1,967,651,000 after purchasing an additional 7,059,171 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Pfizer by 3.3% during the second quarter. Brown Advisory Inc. now owns 1,277,210 shares of the biopharmaceutical company’s stock valued at $46,337,000 after purchasing an additional 41,337 shares during the last quarter. 69.08% of the stock is owned by institutional investors.

PFE has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, July 31st. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, July 31st. Bank of America upped their target price on Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. Morningstar set a $45.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Deutsche Bank set a $45.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 21st. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $42.67.

Shares of PFE stock opened at $43.51 on Monday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The company has a market capitalization of $259.01 billion, a P/E ratio of 16.42, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The business had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. During the same period in the prior year, the company posted $0.67 EPS. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 3 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other news, major shareholder Pfizer Inc bought 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Shares Bought by Braun Bostich & Associates Inc.” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/19/pfizer-inc-pfe-shares-bought-by-braun-bostich-associates-inc.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: What is the NASDAQ?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.